ExoCyte uses flow electroporation to insert exosomes into the dendritic cells, which, when returned to the patient as a vaccine, are armed with the neoantigen messages of the cancer. Other methods of getting the exosome message into dendritic cells, such as co-incubation, are ineffective.
The general principles of electroporation involve the application of an electric field to cells in suspension, causing the cell membranes to become transiently permeable and encouraging external materials, such as peptides, proteins and RNA, to enter the cells. Flow electroporation, co-invented by ExoCyte founder Dr. Holaday, allows electroporation of cells in large volumes in a closed system and is applicable to clinical uses. This technology now resides in the company MaxCyte, Inc. (MXCT, AIM market) based in Gaithersburg, Maryland. MaxCyte (an independent company from ExoCyte) is working with ExoCyte in the development of the ExoCyte vaccine.
The MaxCyte commercial flow electroporation GT device enables transfection of dendritic cells with loading efficiencies exceeding 90%, and is cGMP compliant (FDA-CBER) for human trial use.